featured
Trastuzumab Deruxtecan for Anti-HER2 Therapy–Naïve HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
J. Clin. Oncol 2022 Nov 15;[EPub Ahead of Print], K Yamaguchi, YJ Bang, S Iwasa, N Sugimoto, MH Ryu, D Sakai, HC Chung, H Kawakami, H Yabusaki, J Lee, T Shimoyama, KW Lee, K Saito, Y Kawaguchi, T Kamio, A Kojima, M Sugihara, K ShitaraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.